PolyPid Announces FDA Agreement On Design Of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ For Prevention Of Abdominal Colorectal Surgical Site Infections
Portfolio Pulse from Benzinga Newsdesk
PolyPid announced that the FDA has agreed on the design of the SHIELD II Phase 3 trial, which will evaluate D-PLEX₁₀₀ for the prevention of abdominal colorectal surgical site infections.
May 22, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PolyPid's FDA agreement on the SHIELD II Phase 3 trial design for D-PLEX₁₀₀ may positively impact the company's stock price.
The FDA agreement on the SHIELD II Phase 3 trial design for D-PLEX₁₀₀ is a significant milestone for PolyPid. This regulatory approval may increase investor confidence in the company's product pipeline and potentially lead to a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100